Return to Web Version
Sigma-Aldrich
Life Science > Cell Biology > Antibodies > Prestige Antibodies® > Tools
Antibodies

Prestige Antibodies® as Tools in Detection Studies and Biomarker Discovery

With all the characterization data published on the Human Protein Atlas (HPA) portal (proteinatlas.org), Prestige Antibodies are the most highly characterized antibodies in the industry today. Right now there are over 12,000 Prestige Antibodies available, covering over 10,000 human protein targets. This corresponds to over 50% of the human proteome. Each year more than 2,500 new Prestige Antibodies are made available to the scientific community. The antibodies are directed against both new and previously unknown proteins as well as established protein families.

Each Prestige Antibody has been analyzed and annotated in a large variety of normal and diseased human tissues and the expression profiles are conveniently searchable online. Immunohistochemical (IHC) staining has been performed in 46 normal human tissues, cancer samples covering the 20 most common cancer types, and 56 cell lines and cell lines. In addition, all antibodies have been tested for performance in Immunofluorescence (IF) and Western Blot (WB) applications. In total, more than 700 IHC, as well as ICC, IF and WB images per antibody, are shown online.

Download the Prestige Antibodies as Tools in Detection Studies and Biomarker Discovery (479 Kb PDF) article.

your favorite gene search

powered by ingenuity

Service & Support
Ordering
Corporate

©2011 Sigma-Aldrich Co. LLC. All rights reserved. SIGMA, SAFC, SIGMA-ALDRICH, ALDRICH, and SUPELCO are trademarks of Sigma-Aldrich Co. LLC, registered in the US and other countries. FLUKA is a trademark of Sigma-Aldrich GmbH, registered in the US and other countries. Sigma brand products are sold through Sigma-Aldrich, Inc. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Site Use Terms | Privacy

  • YouTube
  • Twitter
  • LinkedIN
  • Facebook